New Drug Update - Including New Indications and Dosage Forms

After completing this course, the participant should be able to:

  • Discuss the new drugs with respect to their pharmacology, pharmacokinetics, approved and unapproved indications,
  • Describe their adverse effects and drug interactions that may affect patient compliance,
  • Compare efficacy, dosage and cost to existing agents.
  • Discuss the patient oriented outcomes or evidence that may or may not exist for each of the new medications and when they may or may not be appropriate to recommend for selected patients.

Course Content:

  • FDA Safety Alerts
  • Bromocriptine – Cycloset® by VeroScience
  • Quadravalent Human Papillomavirus (Types 6, 11,18) Recombinant Vaccine Gardasil® by Merck
  • Herpes Zoster (Shingles) Vaccine Live Zostavax® by Merck
  • IV Zoledronic acid – Reclast® by Novartis
  • Aliskiren Tekturna/Rasilez® by Novartis
  • Nibivolol – Bystolic® by Forest
  • Simvastatin/Extended Release Niacin – Simcor® by Merck
  • Desvenlafaxine Succinate–Pristiq ® by Wyeth 3. Methylnaltrexone – Relistor ® by Progenics/Wyeth
  • Olopatadine HCl Nasal Spray - Patanase® by Alcon
  • Ciclesonide Nasal Spray - Omnaris® by Altana
  • Ciclesonide Inhalation Aerosol - Alvesco® by Nycome
  • Silodosin – Rapaflo® by Watson 8. Fesoterodine – Toviaz® by Schwarz /Pfizer 1. Febuxostat – Uloric® by TAP
  • Sumatriptan Succinate/Naproxen Sodium - Treximet® by GSK and Pozen 3. Lacosamide – Vimpat® by UCB
  • Dexlansoprazole– Kapidex® by TAP
  • Milnacipran – Savella® by Forest/Cypress 6. Prasugrel – Effient® by Sankyo/Lilly (Not FDA Approved as of 5/09)